Kursprognose für BioCryst Pharmaceuticals, Inc. (BCRX)BCRXBioCryst Pharmaceuticals, Inc.

Alphio's BCRX stock price prediction model matches the current BioCryst Pharmaceuticals, Inc. tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $7.69 (+0.50%). The 1-week path is $7.47 (-2.35%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.

BioCryst Pharmaceuticals Inc (BCRX) is currently not a strong buy due to its recent performance and analyst downgrades. The current price is $7.65, which is below the average analyst price target of $11 to $13, indicating potential upside. However, the RSI is at 30.196, suggesting that the stock is oversold, but it also reflects weak momentum. The company reported a significant net income loss of -721,812,000 USD in Q1 2026, raising concerns about its financial health. The main risk is the competitive pressure from Pharvaris, which could reduce Orladeyo's long-term revenue to $400 million to $450 million, impacting overall performance. Given these factors, it may be prudent to hold rather than buy at this time.

BioCryst Pharmaceuticals, Inc. (BCRX) last closed at $7.65, losing -1.67%. These facts feed the 1-day and 1-week BCRX price prediction above.